Targeting materials and strategies for RNA delivery

RNA-based therapeutics have shown great promise in various medical applications, including cancers, infectious diseases, and metabolic diseases. The recent success of mRNA vaccines for combating the COVID-19 pandemic has highlighted the medical value of RNA drugs. However, one of the major challenges in realizing the full potential of RNA drugs is to deliver RNA into specific organs and tissues in a targeted manner, which is crucial for achieving therapeutic efficacy, reducing side effects, and enhancing overall treatment efficacy. Numerous attempts have been made to pursue targeting, nonetheless, the lack of clear guideline and commonality elucidation has hindered the clinical translation of RNA drugs. In this review, we outline the mechanisms of action for targeted RNA delivery systems and summarize four key factors that influence the targeting delivery of RNA drugs. These factors include the category of vector materials, chemical structures of vectors, administration routes, and physicochemical properties of RNA vectors, and they all notably contribute to specific organ/tissue tropism. Furthermore, we provide an overview of the main RNA-based drugs that are currently in clinical trials, highlighting their design strategies and tissue tropism applications. This review will aid to understand the principles and mechanisms of targeted delivery systems, accelerating the development of future RNA drugs for different

[1]  Yang Liu,et al.  Development of delivery strategies for CRISPR‐Cas9 genome editing , 2023, BMEMat.

[2]  Guoyong Liu,et al.  Tuning the Organ Tropism of Polymersome for Spleen-Selective Nanovaccine Delivery to Boost Cancer Immunotherapy. , 2023, Advanced materials.

[3]  P. Timashev,et al.  Ferritin‐based drug delivery system for tumor therapy , 2023, BMEMat.

[4]  D. McComb,et al.  STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2 , 2023, Nano letters.

[5]  Guangjun Nie,et al.  Current advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles , 2023, BMEMat.

[6]  Margaret M. Billingsley,et al.  Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy. , 2023, Journal of the American Chemical Society.

[7]  H. Cabral,et al.  Polymer‐Based mRNA Delivery Strategies for Advanced Therapies , 2023, Advanced Healthcare Materials.

[8]  Sean A. Dilliard,et al.  Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs , 2023, Nature Reviews Materials.

[9]  Betty Y. S. Kim,et al.  Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy , 2023, Nature Biomedical Engineering.

[10]  Conroy Sun,et al.  Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates , 2023, Science advances.

[11]  D. Weissman,et al.  Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer , 2023, Science advances.

[12]  Hiroki Tanaka,et al.  Delivering mRNA to Secondary Lymphoid Tissues by Phosphatidylserine‐Loaded Lipid Nanoparticles , 2022, Advanced healthcare materials.

[13]  L. Ferreira,et al.  A Polymeric Nanoparticle Formulation for Targeted mRNA Delivery to Fibroblasts , 2022, Advanced science.

[14]  H. Harashima,et al.  Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Z. Li,et al.  Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles , 2022, Materials Today Advances.

[16]  Jong Oh Kim,et al.  Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Pratima Basak,et al.  Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery , 2022, Nature Protocols.

[18]  Shaoyi Jiang,et al.  Zwitterionic Biomaterials. , 2022, Chemical reviews.

[19]  Shaoyi Jiang,et al.  Phosphatidylserine Lipid Nanoparticles Promote Systemic RNA Delivery to Secondary Lymphoid Organs. , 2022, Nano letters.

[20]  S. Chatterjee,et al.  Lipid Nanoparticle (LNP) Chemistry Can Endow Unique In Vivo RNA Delivery Fates within the Liver That Alter Therapeutic Outcomes in a Cancer Model. , 2022, Molecular pharmaceutics.

[21]  Jeonghwan Kim,et al.  Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation. , 2022, ACS nano.

[22]  A. Aigner,et al.  Therapeutic siRNA: State-of-the-Art and Future Perspectives , 2022, BioDrugs.

[23]  James E. Dahlman,et al.  Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo , 2022, Nature Communications.

[24]  Xingxu Huang,et al.  Helper-Polymer Based Five-Element Nanoparticles (FNPs) for Lung-Specific mRNA Delivery with Long-Term Stability after Lyophilization. , 2022, Nano letters.

[25]  X. Xiang,et al.  Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment. , 2022, Cytokine & growth factor reviews.

[26]  B. Hoppe,et al.  Improving Treatment Options for Primary Hyperoxaluria , 2022, Drugs.

[27]  S. Mitragotri,et al.  RNA therapeutics in the clinic , 2022, Bioengineering & translational medicine.

[28]  Santosh K Bashyal,et al.  Recent progresses in exosome-based systems for targeted drug delivery to the brain. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[29]  J. Bacchetta,et al.  Genetic assessment in primary hyperoxaluria: why it matters , 2022, Pediatric Nephrology.

[30]  Timothy A. Miller,et al.  Antisense Oligonucleotides for the Study and Treatment of ALS , 2022, Neurotherapeutics.

[31]  D. Weissman,et al.  Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment. , 2022, Journal of the American Chemical Society.

[32]  Yi Hong,et al.  Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy , 2022, Nature Nanotechnology.

[33]  Chunying Chen,et al.  Chemical and Biophysical Signatures of the Protein Corona in Nanomedicine. , 2022, Journal of the American Chemical Society.

[34]  M. Emdin,et al.  RNA-targeting and gene editing therapies for transthyretin amyloidosis , 2022, Nature Reviews Cardiology.

[35]  T. Sharp,et al.  Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System , 2022, Advanced materials.

[36]  Qiaobing Xu,et al.  Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis , 2022, Proceedings of the National Academy of Sciences.

[37]  M. Coelho,et al.  Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma , 2022, Pharmaceutics.

[38]  Margaret A. Liu,et al.  WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021 , 2022, Emerging microbes & infections.

[39]  Jiancheng Wang,et al.  Non-viral vectors for RNA delivery , 2022, Journal of Controlled Release.

[40]  D. Weissman,et al.  CAR T cells produced in vivo to treat cardiac injury , 2022, Science.

[41]  D. Zack,et al.  High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA , 2022, Science advances.

[42]  Qiang Cheng,et al.  On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles , 2021, Proceedings of the National Academy of Sciences.

[43]  James E. Dahlman,et al.  Non-liver mRNA Delivery. , 2021, Accounts of chemical research.

[44]  Jeonghwan Kim,et al.  Chemistry of Lipid Nanoparticles for RNA Delivery. , 2021, Accounts of chemical research.

[45]  W. Tarn,et al.  Antisense Oligonucleotide-Based Therapy of Viral Infections , 2021, Pharmaceutics.

[46]  M. Martínez-García,et al.  Polymer-dendrimer hybrids as carriers of anticancer agents. , 2021, Current drug targets.

[47]  R. Langer,et al.  Nucleic Acid Delivery for Therapeutic Applications. , 2021, Advanced drug delivery reviews.

[48]  B. Hoppe,et al.  Safety, pharmacodynamics, and exposure-response modeling results from a first in human phase 1 study of nedosiran in primary hyperoxaluria. , 2021, Kidney international.

[49]  James E. Dahlman,et al.  Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs , 2021, Nature Biomedical Engineering.

[50]  P. Giangrande,et al.  Advances in mRNA non-viral delivery approaches. , 2021, Advanced drug delivery reviews.

[51]  K. Ganbarov,et al.  SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review , 2021, International Journal of Biological Macromolecules.

[52]  R. Langer,et al.  Lipid nanoparticles for mRNA delivery , 2021, Nature Reviews Materials.

[53]  G. Song,et al.  Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. , 2021, Journal of hepatology.

[54]  B. Cowling,et al.  Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 , 2021, The Lancet Microbe.

[55]  D. Matei,et al.  The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer , 2021, Cancer Research.

[56]  Daniel G. Anderson,et al.  Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles. , 2021, Biomaterials.

[57]  D. Weissman,et al.  Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  A. Aljabali,et al.  siRNA: Mechanism of action, challenges, and therapeutic approaches. , 2021, European journal of pharmacology.

[59]  M. Imperiale,et al.  Biology of Polyomavirus miRNA , 2021, Frontiers in Microbiology.

[60]  S. Crooke,et al.  Antisense technology: an overview and prospectus , 2021, Nature Reviews Drug Discovery.

[61]  Mary E. Haas,et al.  Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 , 2021, Proceedings of the National Academy of Sciences.

[62]  Lukas Farbiak,et al.  Membrane destabilizing ionizable phospholipids for organ selective mRNA delivery and CRISPR/Cas gene editing , 2021, Nature Materials.

[63]  Q. Qian,et al.  Therapeutic Mechanism of Nucleic Acid Drugs , 2021 .

[64]  G. Ariceta,et al.  Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria , 2021, Kidney international reports.

[65]  K. Nam,et al.  Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver , 2021, Science Advances.

[66]  Zhujun Cheng,et al.  The Risks of miRNA Therapeutics: In a Drug Target Perspective , 2021, Drug design, development and therapy.

[67]  A. Waisman,et al.  A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis , 2021, Science.

[68]  Jeonghwan Kim,et al.  Self-assembled mRNA vaccines , 2021, Advanced Drug Delivery Reviews.

[69]  Turkan Kopac,et al.  Protein corona, understanding the nanoparticle-protein interactions and future perspectives: A critical review. , 2020, International journal of biological macromolecules.

[70]  Qiang Cheng,et al.  A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo. , 2020, Angewandte Chemie.

[71]  Nicholas A. Peppas,et al.  Engineering precision nanoparticles for drug delivery , 2020, Nature reviews. Drug discovery.

[72]  S. Solomon,et al.  Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study , 2020, European heart journal.

[73]  Siddharth Patel,et al.  The effects of PEGylation on LNP based mRNA delivery to the eye , 2020, PloS one.

[74]  M. Gyöngyösi,et al.  CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure , 2020, European heart journal.

[75]  M. Wood,et al.  Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  Michael Y. T. Chow,et al.  Inhaled RNA Therapy: From Promise to Reality , 2020, Trends in Pharmacological Sciences.

[77]  R. Langer,et al.  Advances in oligonucleotide drug delivery , 2020, Nature Reviews Drug Discovery.

[78]  Luis A. Barrera,et al.  Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing , 2020, Science Advances.

[79]  Daniel G. Anderson,et al.  Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing. , 2020, ACS nano.

[80]  Qiaobing Xu,et al.  Imidazole-based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes. , 2020, Angewandte Chemie.

[81]  Qiang Cheng,et al.  Theranostic dendrimer-based lipid nanoparticles containing PEGylated BODIPY dyes for tumor imaging and systemic mRNA delivery in vivo. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[82]  Qiaobing Xu,et al.  Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection , 2020, Science Advances.

[83]  J. Karp,et al.  BBB pathophysiology independent delivery of siRNA in traumatic brain injury , 2020, bioRxiv.

[84]  E. Olson,et al.  Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing , 2020, Nature Communications.

[85]  W. Saltzman,et al.  Polymeric vehicles for nucleic acid delivery. , 2020, Advanced drug delivery reviews.

[86]  J. Heyes,et al.  Lipid nanoparticles for nucleic acid delivery: Current perspectives. , 2020, Advanced drug delivery reviews.

[87]  Khalid A. Hajj,et al.  A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo. , 2020, Nano letters.

[88]  R. Bahal,et al.  Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy , 2020, Molecules.

[89]  J. Knuuti,et al.  Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial , 2020, Molecular therapy. Methods & clinical development.

[90]  Bruna dos Santos Rodrigues,et al.  In Vitro and In Vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA. , 2020, Nanomedicine : nanotechnology, biology, and medicine.

[91]  J. Yewdell,et al.  Decoding mRNA translatability and stability from the 5′ UTR , 2020, Nature Structural & Molecular Biology.

[92]  Qiang Cheng,et al.  Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing , 2020, Nature Nanotechnology.

[93]  Qiang Cheng,et al.  Lipid‐Modified Aminoglycosides for mRNA Delivery to the Liver , 2020, Advanced healthcare materials.

[94]  James E. Dahlman,et al.  Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands , 2020, Bioengineering & translational medicine.

[95]  Siddharth Patel,et al.  Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA , 2020, Nature Communications.

[96]  A. Ortiz,et al.  Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease , 2020, Clinical kidney journal.

[97]  L. Scott Givosiran: First Approval , 2020, Drugs.

[98]  R. Gemeinhart,et al.  Toward understanding polymer micelle stability: Density ultracentrifugation offers insight into polymer micelle stability in human fluids. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[99]  Do Won Hwang,et al.  Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[100]  C. Vanhove,et al.  Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[101]  T. Andresen,et al.  Targeting the transferrin receptor for brain drug delivery , 2019, Progress in Neurobiology.

[102]  B. Newland,et al.  Highly branched poly(β-amino ester) delivery of minicircle DNA for transfection of neurodegenerative disease related cells , 2019, Nature Communications.

[103]  A. Jimeno,et al.  Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade , 2019, Clinical Trials.

[104]  Jordan J. Green,et al.  Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery , 2019, Advanced materials.

[105]  Gaurav Sahay,et al.  Lipid nanoparticles for delivery of messenger RNA to the back of the eye. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Ryan L Setten,et al.  The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.

[107]  Manish R. Patel,et al.  A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. , 2019, Journal of Clinical Oncology.

[108]  B. Rothen‐Rutishauser,et al.  Polymer-Coated Gold Nanospheres Do Not Impair the Innate Immune Function of Human B Lymphocytes in Vitro. , 2019, ACS Nano.

[109]  Jingwen Sun,et al.  Copper Sulfide Facilitates Hepatobiliary Clearance of Gold Nanoparticles through the Copper-Transporting ATPase ATP7B. , 2019, ACS nano.

[110]  Hao Yin,et al.  Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  I. Sahu,et al.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[112]  Daniel G Anderson,et al.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  D. Offen,et al.  Golden Exosomes Selectively Target Brain Pathologies in Neurodegenerative and Neurodevelopmental Disorders. , 2019, Nano letters.

[114]  Khalid A. Hajj,et al.  Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH. , 2019, Small.

[115]  C. Bennett Therapeutic Antisense Oligonucleotides Are Coming of Age. , 2019, Annual review of medicine.

[116]  Robert Langer,et al.  Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium , 2019, Advanced materials.

[117]  I. Papangeli,et al.  CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations. , 2018, Seminars in perinatology.

[118]  N. Pedemonte,et al.  Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis , 2018, Scientific Reports.

[119]  Dan Peer,et al.  Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes , 2018, Nature Communications.

[120]  Philip J. Santangelo,et al.  High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing , 2018, Proceedings of the National Academy of Sciences.

[121]  Hao Zhou,et al.  Zinc Coordinated Cationic Polymers Break Up the Paradox between Low Molecular Weight and High Transfection Efficacy. , 2018, Biomacromolecules.

[122]  Kaitlyn Sadtler,et al.  Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells. , 2018, Nano letters.

[123]  Daniel G. Anderson,et al.  Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs. , 2018, Angewandte Chemie.

[124]  K. Garber Alnylam launches era of RNAi drugs , 2018, Nature Biotechnology.

[125]  C. Mayr What Are 3' UTRs Doing? , 2018, Cold Spring Harbor perspectives in biology.

[126]  R. Tarran,et al.  The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease , 2018, Expert opinion on therapeutic targets.

[127]  Robert Langer,et al.  Ionizable Amino‐Polyesters Synthesized via Ring Opening Polymerization of Tertiary Amino‐Alcohols for Tissue Selective mRNA Delivery , 2018, Advanced materials.

[128]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[129]  E. Salido,et al.  Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[130]  R. Waymouth,et al.  Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters , 2018, Proceedings of the National Academy of Sciences.

[131]  Yizhou Dong,et al.  Co-delivery of mRNA and SPIONs through amino-ester nanomaterials , 2018, Nano Research.

[132]  O. Farokhzad,et al.  Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy. , 2018, Trends in biotechnology.

[133]  W. Harrington,et al.  A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. , 2018, Cell reports.

[134]  P. Trivedi,et al.  Advances in siRNA delivery in cancer therapy , 2018, Artificial cells, nanomedicine, and biotechnology.

[135]  J. Lieberman,et al.  A modular platform for targeted RNAi therapeutics , 2018, Nature Nanotechnology.

[136]  B. Kumar,et al.  Promising Targets in Anti-cancer Drug Development: Recent Updates. , 2018, Current medicinal chemistry.

[137]  Yoosoo Yang,et al.  Cancer‐derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism‐dependent targeting , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[138]  Qiang Cheng,et al.  Systemic mRNA Delivery to the Lungs by Functional Polyester-based Carriers. , 2017, Biomacromolecules.

[139]  Daniel G. Anderson,et al.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.

[140]  Khalid A. Hajj,et al.  Tools for translation: non-viral materials for therapeutic mRNA delivery , 2017 .

[141]  Jiayi Pan,et al.  Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy , 2017, Molecules.

[142]  Kimberly J. Hassett,et al.  Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[143]  J. Ulmer,et al.  Mechanism of action of mRNA-based vaccines , 2017, Expert review of vaccines.

[144]  S. Newman Drug delivery to the lungs: challenges and opportunities. , 2017, Therapeutic delivery.

[145]  Bin Li,et al.  Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo. , 2017, ACS applied materials & interfaces.

[146]  Shuai Liu,et al.  Alkylated branched poly(β-amino esters) demonstrate strong DNA encapsulation, high nanoparticle stability and robust gene transfection efficacy. , 2017, Journal of materials chemistry. B.

[147]  Wenxin Wang,et al.  Biodegradable Highly Branched Poly(β-Amino Ester)s for Targeted Cancer Cell Gene Transfection. , 2017, ACS biomaterials science & engineering.

[148]  Mark W. Tibbitt,et al.  Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes , 2017, Advanced materials.

[149]  P. Cullis,et al.  Lipid Nanoparticle Systems for Enabling Gene Therapies. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[150]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[151]  Shuai Liu,et al.  Bioreducible Zinc(II)-Coordinative Polyethylenimine with Low Molecular Weight for Robust Gene Delivery of Primary and Stem Cells. , 2017, Journal of the American Chemical Society.

[152]  W. Baumgartner,et al.  Generation‐6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[153]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[154]  S. Dowdy Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.

[155]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[156]  Daniel G Anderson,et al.  Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs. , 2016, Angewandte Chemie.

[157]  Y. Yeo,et al.  Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. , 2016, Advanced drug delivery reviews.

[158]  Vladimir P Torchilin,et al.  Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue. , 2016, Small.

[159]  C. Rudolph,et al.  A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery. , 2016, Angewandte Chemie.

[160]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[161]  K. Whitehead,et al.  Lipidoid Tail Structure Strongly Influences siRNA Delivery Activity , 2016 .

[162]  Thomas D. Schmittgen,et al.  Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA , 2016, Scientific Reports.

[163]  Mark W. Tibbitt,et al.  Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery , 2016, Advanced materials.

[164]  Jun Zhu,et al.  Inferred miRNA activity identifies miRNA-mediated regulatory networks underlying multiple cancers , 2015, Bioinform..

[165]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[166]  G. Salzano,et al.  Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer , 2015, Molecular Cancer Therapeutics.

[167]  G. Szabo,et al.  Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[168]  Meg Duroux,et al.  A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. , 2014, Biochimica et biophysica acta.

[169]  V. Kim,et al.  TAIL-seq: genome-wide determination of poly(A) tail length and 3' end modifications. , 2014, Molecular cell.

[170]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[171]  Ronald A. Li,et al.  Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction , 2013, Nature Biotechnology.

[172]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[173]  M. Wood,et al.  Exosome nanotechnology: An emerging paradigm shift in drug delivery , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[174]  Joseph M. DeSimone,et al.  Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles , 2011, Proceedings of the National Academy of Sciences.

[175]  B. Campbell,et al.  RNA interference: a chemist's perspective. , 2010, Chemical Society reviews.

[176]  Leaf Huang,et al.  Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[177]  P. Devarajan,et al.  Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. , 2010, Journal of pharmaceutical sciences.

[178]  F. Dammacco,et al.  Targeted therapies in cancer , 2018, Surgery (Oxford).

[179]  Sei-Young Lee,et al.  Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows , 2009, Nanotechnology.

[180]  J. Cavaille,et al.  C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts , 2009, Nucleic acids research.

[181]  J. Watts,et al.  Chemically modified siRNA: tools and applications. , 2008, Drug discovery today.

[182]  M Ferrari,et al.  The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. , 2008, Journal of biomechanics.

[183]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[184]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[185]  V. Rotello,et al.  Drug and gene delivery using gold nanoparticles , 2007 .

[186]  U. Şahin,et al.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. , 2006, Blood.

[187]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[188]  Fumiyoshi Yamashita,et al.  The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[189]  C. Porter,et al.  Subcutaneous drug delivery and the role of the lymphatics. , 2005, Drug discovery today. Technologies.

[190]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[191]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[192]  N. Sonenberg,et al.  The major mRNA‐associated protein YB‐1 is a potent 5′ cap‐dependent mRNA stabilizer , 2001, The EMBO journal.

[193]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[194]  N. Sonenberg,et al.  eIF4G Dramatically Enhances the Binding of eIF4E to the mRNA 5′-Cap Structure* , 1997, The Journal of Biological Chemistry.

[195]  H. J. Kim,et al.  Engineered Lipid Nanoparticles for the Treatment of Pulmonary Fibrosis by Regulating Epithelial‐Mesenchymal Transition in the Lungs , 2023 .

[196]  P. Dřevínek,et al.  Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[197]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[198]  Warren C W Chan,et al.  Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.

[199]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[200]  Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes , 2022 .